Jiangbo Pharmaceuticals (ehem. GNPH) - A0RNJB/JGBO
Komisch dass ich das medikament auf der JGBO Webseite noch nie gesehen habe...hehehe
Scheit wohl was in der pipeline zu sein.... :-)
Muss wohl eines der 11 weiteren Medikamente sein die sehr bald produziert werden.
Also bis später..muss jetzt dringend weg...falls jemand was auf dem geheimen Upload verzeichniss entdeckt bitte gerne posten, noch habe ich mir nicht alles angesehen, da sind bestimmt noch Kleinigkeiten zu finden welche nicht public sind. (So wie das noch unbekannte Produkt oben)
l8er
Wenn nicht jetzt wann dann ??
Ach und die GMP rezertifizierung ist durch...also bis 2014 keine produktionsstops... !!!!!!!!!!!!!!!!!!!!!!!!!!!
Kaufen mit beiden Händen voll zulangen...ihr werdet sehen...uplisting wird kommen weswegen sonst die 3 "amended" filings...ich hab da sehr grosse Hoffnungen... :-)
LALA.....LALA....LALA....
http://www.china-hilead.com/en/shipin.asp
Love Donation For The Ill Girl
"Love Donation For The Ill Girl" in our company activities on March 24, 2010. under the spirit of the company and the call of corporate culture"s influence. All the people in Hilead try their best to help the girl.
Shu Fang, 11 years old. Her father is a teacher of Primary school. The girl was recognized as a bone cancer in Beijing Jishuitan Hospital in the 9th,October, 2009. To help her overcome the disease and return to school earlier, All the staff sincere love and dedication with practical actions. Passage of time, accumulation of small, condensed each love, light heart Brilliant. Roll up life to life. Gave her a warm hands, Sincerely look forward to healthy.
Until now, we received contributions over fifty five thousand and it will be sent to her as soon as possible.
Best wishes to her and hope she can re-enjoy a happy family life!
http://www.china-hilead.com/en/shownews.asp?id=187
Love Donation For The Ill Girl
"Love Donation For The Ill Girl" in our company activities on March 24, 2010. under the spirit of the company and the call of corporate culture"s influence. All the people in Hilead try their best to help the girl.
Shu Fang, 11 years old. Her father is a teacher of Primary school. The girl was recognized as a bone cancer in Beijing Jishuitan Hospital in the 9th,October, 2009. To help her overcome the disease and return to school earlier, All the staff sincere love and dedication with practical actions. Passage of time, accumulation of small, condensed each love, light heart Brilliant. Roll up life to life. Gave her a warm hands, Sincerely look forward to healthy.
Until now, we received contributions over fifty five thousand and it will be sent to her as soon as possible.
Best wishes to her and hope she can re-enjoy a happy family life!
http://www.china-hilead.com/en/shownews.asp?id=187
P.S. Cao Wubo , Ceo of JGBO is President @ HILEAD !!!
More Info and Pictures..
http://www.china-hilead.com/en/shownews.asp?id=169
http://www.sec.gov/Archives/edgar/data/1091164/...4/v187289_8a12b.htm
Buzz up! 0 Print..Companies:JIANGBO PHARMACEUTCL.Related Quotes
Symbol Price Change
JGBO.OB 8.44 0.00
Press Release Source: Jiangbo Pharmaceuticals, Inc. On Friday June 4, 2010, 9:00 am
LAIYANG, China, June 4 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board:JGBO.ob - News) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that the Company has received approval to list its common stock on the NASDAQ Global Market.
Jiangbo anticipates that its common stock will begin trading on the NASDAQ Global Market on Tuesday, June 8, 2010, under the symbol "JGBO". Until that time, the Company's common stock will continue to trade on the Over-the-Counter Bulletin Board under the symbol "JGBO".
"We are extremely pleased to meet the listing standards for NASDAQ Global Market, one of the world's preeminent stock exchanges, and would like to thank all of our supporters, including our investors and employees," commented Mr. Wubo Cao, the Company's Chief Executive Officer. "We view this upgrade as a significant milestone in Jiangbo's development as a U.S. publicly-traded company. We anticipate the move to the NASDAQ Global Market to help to increase the Company's visibility in the investment community, improved trading liquidity and broaden our shareholder base."
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website http://www.jiangbopharma.com .
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the significance of the Company's listing on the NASDAQ Global Market, ability to obtain raw materials needed in manufacturing, anticipated sales volume growth of the medicines, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact: Jiangbo Pharmaceuticals, Inc. Ms. Elsa Sung, CFO Phone: +1-954-903-9378 Email: elsasung@jiangbo.com Web: http://www.jiangbopharma.com CCG Investor Relations Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: lei.huang@ccgir.com Web: http://www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 Email: crocker.coulson@ccgir.com
http://finance.yahoo.com/news/...-prnews-259371251.html?x=0&.v=91
--------------------------------------------------
4-Jun-2010
Other Events, Financial Statements and Exhibits
Item 8.01 Other Event.
On June 4, 2010, Jiangbo Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it had been approved for listing on The Nasdaq Global Market and would commence trading under the symbol "JGBO" on June 8, 2010. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press Release dated June 4, 2010.
http://biz.yahoo.com/e/100604/jgbo.ob8-k.html
Da haben die heute nochmal das letzte GAP mit gewalt geschlossen..ein glück sind wir ab morgen weg von der OTC Schei$$e... :-)
